Payment overview · 2025
General Payments
$103.55
6 reported records · 6 companies
Healthcare provider profile · identity verified
Christopher Harvey Bracey, FNP
Allopathic & Osteopathic Physicians|Family Medicine · MCCOMB, MS · NPI 1578084521
Verified facts
What the public records show
CMS Open Payments records show Christopher Harvey Bracey, FNP received $103.55 in general payments during 2025 across 6 reported records.
Boston Scientific Corporation accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.47 | 22.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.63 | 19.0% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $16.88 | 16.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.06 | 15.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.96 | 15.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.55 | 11.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $103.55 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ROTAPRO Normalized: rotapro |
Device | Boston Scientific Corporation | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 65 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
65 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 419 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 399 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 292 | 65 |
| Losartan Potassium | Losartan Potassium | 285 | 64 |
| Gabapentin | Gabapentin | 260 | 62 |
| Metformin Hcl | Metformin Hcl | 231 | 53 |
| Atorvastatin Calcium | Atorvastatin Calcium | 211 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 207 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 206 | 54 |
| Furosemide | Furosemide | 181 | 48 |
| Omeprazole | Omeprazole | 163 | 40 |
| Potassium Chloride | Potassium Chloride | 160 | 43 |
| Lisinopril | Lisinopril | 135 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 125 | 25 |
| Azithromycin | Azithromycin | 120 | 104 |
| Tamsulosin Hcl | Tamsulosin Hcl | 116 | 27 |
| Trazodone Hcl | Trazodone Hcl | 114 | 26 |
| Meloxicam | Meloxicam | 111 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 30 |
| Allopurinol | Allopurinol | 106 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 19 |
| Montelukast Sodium | Montelukast Sodium | 99 | 20 |
| Buspirone Hcl | Buspirone Hcl | 93 | 25 |
| Glimepiride | Glimepiride | 93 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 92 | 40 |
| Warfarin Sodium | Warfarin Sodium | 92 | suppressed |
| Carvedilol | Carvedilol | 88 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 39 |
| Sertraline Hcl | Sertraline Hcl | 85 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 14 |
| Farxiga | Dapagliflozin Propanediol | 72 | 17 |
| Glipizide | Glipizide | 71 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 19 |
| Dexamethasone | Dexamethasone | 65 | 57 |
| Jardiance | Empagliflozin | 65 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 63 | 55 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | 16 |
| Ezetimibe | Ezetimibe | 59 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 15 |
| Eliquis | Apixaban | 56 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 16 |
| Fluconazole | Fluconazole | 55 | 39 |
| Tramadol Hcl | Tramadol Hcl | 49 | 28 |
| Methocarbamol | Methocarbamol | 44 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Colchicine | Colchicine | 42 | 14 |
| Alendronate Sodium | Alendronate Sodium | 41 | suppressed |
| Prednisone | Prednisone | 40 | 21 |
| Meclizine Hcl | Meclizine Hcl | 38 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 25 |
| Famotidine | Famotidine | 34 | 14 |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Simvastatin | Simvastatin | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Celecoxib | Celecoxib | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 27 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 25 |
| Topiramate | Topiramate | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 25 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Nystatin | Nystatin | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | 12 |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 12 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $103.55 · 6 records | Boston Scientific Corporation | JARDIANCE, OTEZLA, REPATHA, ROTAPRO, TRELEGY ELLIPTA, VOQUEZNA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error